Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Bays

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Current Medical Research and Opinion|November 8, 2016
Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effectsHarold Bays, Xavier Pi-Sunyer, Joanna Uddén Hemmingsson, et al.
Cardiovascular Drugs and Therapy|April 5, 2021
Role of Bempedoic Acid in Clinical PracticeChristie M Ballantyne, Harold Bays, Alberico L Catapano, et al.
Nutrition & Metabolism|August 18, 2011
Reduced viscosity Barley β-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitusHarold Bays, Joy L Frestedt, Margie Bell, et al.
Cardiovascular Drugs and Therapy|April 19, 2021
Correction to: Role of Bempedoic Acid in Clinical PracticeChristie M Ballantyne, Harold Bays, Alberico L Catapano, et al.
Diabetes Care|October 23, 2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetesPriscilla Hollander, Alok K Gupta, Raymond Plodkowski, et al.
Journal of Clinical Lipidology|May 6, 2014
An assessment by the Statin Liver Safety Task Force: 2014 updateHarold Bays, David E Cohen, Naga Chalasani, et al.
European Heart Journal Open|September 22, 2025
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trialMamas A Mamas, Harold Bays, Runjia Li, et al.
Lipids in Health and Disease|December 2, 2010
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Harold Bays, Scott Conard, Lawrence A Leiter, et al.
The New England Journal of Medicine|July 22, 2010
Multicenter, placebo-controlled trial of lorcaserin for weight managementSteven R Smith, Neil J Weissman, Christen M Anderson, et al.
The American Journal of Cardiology|November 26, 2008
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart diseaseLawrence A Leiter, Harold Bays, Scott Conard, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Current Medical Research and Opinion|November 8, 2016
Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effectsHarold Bays, Xavier Pi-Sunyer, Joanna Uddén Hemmingsson, et al.
Cardiovascular Drugs and Therapy|April 5, 2021
Role of Bempedoic Acid in Clinical PracticeChristie M Ballantyne, Harold Bays, Alberico L Catapano, et al.
Nutrition & Metabolism|August 18, 2011
Reduced viscosity Barley β-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitusHarold Bays, Joy L Frestedt, Margie Bell, et al.
Cardiovascular Drugs and Therapy|April 19, 2021
Correction to: Role of Bempedoic Acid in Clinical PracticeChristie M Ballantyne, Harold Bays, Alberico L Catapano, et al.
Diabetes Care|October 23, 2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetesPriscilla Hollander, Alok K Gupta, Raymond Plodkowski, et al.
Journal of Clinical Lipidology|May 6, 2014
An assessment by the Statin Liver Safety Task Force: 2014 updateHarold Bays, David E Cohen, Naga Chalasani, et al.
European Heart Journal Open|September 22, 2025
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trialMamas A Mamas, Harold Bays, Runjia Li, et al.
Lipids in Health and Disease|December 2, 2010
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Harold Bays, Scott Conard, Lawrence A Leiter, et al.
The New England Journal of Medicine|July 22, 2010
Multicenter, placebo-controlled trial of lorcaserin for weight managementSteven R Smith, Neil J Weissman, Christen M Anderson, et al.
The American Journal of Cardiology|November 26, 2008
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart diseaseLawrence A Leiter, Harold Bays, Scott Conard, et al.
Pageof 8